Literature DB >> 26580159

Medicine: Eyes on the target.

Michael Eisenstein.   

Abstract

Mesh:

Substances:

Year:  2015        PMID: 26580159     DOI: 10.1038/527S110a

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  10 in total

1.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Authors:  José Baselga; Javier Cortés; Sung-Bae Kim; Seock-Ah Im; Roberto Hegg; Young-Hyuck Im; Laslo Roman; José Luiz Pedrini; Tadeusz Pienkowski; Adam Knott; Emma Clark; Mark C Benyunes; Graham Ross; Sandra M Swain
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

3.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

Authors:  Luca Gianni; Tadeusz Pienkowski; Young-Hyuck Im; Laslo Roman; Ling-Ming Tseng; Mei-Ching Liu; Ana Lluch; Elżbieta Staroslawska; Juan de la Haba-Rodriguez; Seock-Ah Im; Jose Luiz Pedrini; Brigitte Poirier; Paolo Morandi; Vladimir Semiglazov; Vichien Srimuninnimit; Giulia Bianchi; Tania Szado; Jayantha Ratnayake; Graham Ross; Pinuccia Valagussa
Journal:  Lancet Oncol       Date:  2011-12-06       Impact factor: 41.316

4.  HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.

Authors:  Shanu Modi; Alison Stopeck; Hannah Linden; David Solit; Sarat Chandarlapaty; Neal Rosen; Gabriella D'Andrea; Maura Dickler; Mary E Moynahan; Steven Sugarman; Weining Ma; Sujata Patil; Larry Norton; Alison L Hannah; Clifford Hudis
Journal:  Clin Cancer Res       Date:  2011-05-10       Impact factor: 12.531

5.  Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.

Authors:  Mario Giuliano; Huizhong Hu; Yen-Chao Wang; Xiaoyong Fu; Agostina Nardone; Sabrina Herrera; Sufeng Mao; Alejandro Contreras; Carolina Gutierrez; Tao Wang; Susan G Hilsenbeck; Carmine De Angelis; Nicholas J Wang; Laura M Heiser; Joe W Gray; Sara Lopez-Tarruella; Anne C Pavlick; Meghana V Trivedi; Gary C Chamness; Jenny C Chang; C Kent Osborne; Mothaffar F Rimawi; Rachel Schiff
Journal:  Clin Cancer Res       Date:  2015-05-26       Impact factor: 12.531

6.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

7.  Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).

Authors:  A Schneeweiss; S Chia; T Hickish; V Harvey; A Eniu; R Hegg; C Tausch; J H Seo; Y-F Tsai; J Ratnayake; V McNally; G Ross; J Cortés
Journal:  Ann Oncol       Date:  2013-05-22       Impact factor: 32.976

8.  In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Authors:  Ayalew Tefferi; Hagop Kantarjian; S Vincent Rajkumar; Lawrence H Baker; Jan L Abkowitz; John W Adamson; Ranjana Hira Advani; James Allison; Karen H Antman; Robert C Bast; John M Bennett; Edward J Benz; Nancy Berliner; Joseph Bertino; Ravi Bhatia; Smita Bhatia; Deepa Bhojwani; Charles D Blanke; Clara D Bloomfield; Linda Bosserman; Hal E Broxmeyer; John C Byrd; Fernando Cabanillas; George Peter Canellos; Bruce A Chabner; Asher Chanan-Khan; Bruce Cheson; Bayard Clarkson; Susan L Cohn; Gerardo Colon-Otero; Jorge Cortes; Steven Coutre; Massimo Cristofanilli; Walter J Curran; George Q Daley; Daniel J DeAngelo; H Joachim Deeg; Lawrence H Einhorn; Harry P Erba; Francisco J Esteva; Elihu Estey; Isaiah J Fidler; James Foran; Stephen Forman; Emil Freireich; Charles Fuchs; James N George; Morie A Gertz; Sergio Giralt; Harvey Golomb; Peter Greenberg; Jordan Gutterman; Robert I Handin; Samuel Hellman; Paulo Marcelo Hoff; Ronald Hoffman; Waun Ki Hong; Mary Horowitz; Gabriel N Hortobagyi; Clifford Hudis; Jean Pierre Issa; Bruce Evan Johnson; Philip W Kantoff; Kenneth Kaushansky; David Khayat; Fadlo R Khuri; Thomas J Kipps; Margaret Kripke; Robert A Kyle; Richard A Larson; Theodore S Lawrence; Ross Levine; Michael P Link; Scott M Lippman; Sagar Lonial; Gary H Lyman; Maurie Markman; John Mendelsohn; Neal J Meropol; Yoav Messinger; Therese M Mulvey; Susan O'Brien; Roman Perez-Soler; Raphael Pollock; Josef Prchal; Oliver Press; Jerald Radich; Kanti Rai; Saul A Rosenberg; Jacob M Rowe; Hope Rugo; Carolyn D Runowicz; Brenda M Sandmaier; Alan Saven; Andrew I Schafer; Charles Schiffer; Mikkael A Sekeres; Richard T Silver; Lillian L Siu; David P Steensma; F Marc Stewart; Wendy Stock; Richard Stone; Rainer Storb; Louise C Strong; Martin S Tallman; Michael Thompson; Naoto T Ueno; Richard A Van Etten; Julie M Vose; Peter H Wiernik; Eric P Winer; Anas Younes; Andrew D Zelenetz; Charles A LeMaistre
Journal:  Mayo Clin Proc       Date:  2015-07-23       Impact factor: 7.616

9.  Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.

Authors:  Thomas Bachelot; Gilles Romieu; Mario Campone; Véronique Diéras; Claire Cropet; Florence Dalenc; Marta Jimenez; Emilie Le Rhun; Jean-Yves Pierga; Anthony Gonçalves; Marianne Leheurteur; Julien Domont; Maya Gutierrez; Hervé Curé; Jean-Marc Ferrero; Catherine Labbe-Devilliers
Journal:  Lancet Oncol       Date:  2012-11-02       Impact factor: 41.316

10.  Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA.

Authors:  S M Swain; J Baselga; D Miles; Y-H Im; C Quah; L F Lee; J Cortés
Journal:  Ann Oncol       Date:  2014-03-31       Impact factor: 32.976

  10 in total
  2 in total

Review 1.  ErbB2 signaling at the crossing between heart failure and cancer.

Authors:  Zarha Vermeulen; Vincent F M Segers; Gilles W De Keulenaer
Journal:  Basic Res Cardiol       Date:  2016-09-05       Impact factor: 17.165

Review 2.  Cdk5 links with DNA damage response and cancer.

Authors:  Wan Liu; Jun Li; Yu-Shu Song; Yue Li; Yu-Hong Jia; Hai-Dong Zhao
Journal:  Mol Cancer       Date:  2017-03-14       Impact factor: 27.401

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.